The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng.

Slides:

Advertisements

Similar presentations

PARP Inhibitors for the treatment of MPNST

Advertisements

INTEGRATED ANALYSIS OF THE MOLECULAR DEREGULATIONS OF THE MDM2:P53 AXIS IN DDLPS KATE LYNN BILL, JEANNINE GARNETT, CHAD CREIGHTON, XIAOYAN MA, ISABELLE.

Biological pathway and systems analysis An introduction.

Medical Genetics & Genomics Guri Tzivion, PhD Extension 506 BCHM 560: January 2015 Windsor University School of Medicine.

Raphael Pollock, MD, PhD Principal Investigator

SERUM DEPRIVATION INDUCES EWING SARCOMA CELLS TO ADOPT A MORE INVASIVE PHENOTYPE AND TO UP REGULATE RHO-MKL TRANSCRIPTIONAL SIGNALING Merlin Airik, Melanie.

Urokinase Plasminogen Activator (uPA) and its Receptor uPAR.

Lecture 10: Cell Communication II. GPCR signaling is inactivated by arrestins.

Therapeutic Implications and Prognostic Significance of c-Met in Esophageal Squamous Cell Cancer Ching Tzao 1, Chun-Ya Wang 1, Ban-Hen Chen 1, Guang-Huan.

Literature Report 李丽婷 Article source : Gut 2013;62:

Sarcoma Research Laboratory University of Texas, MD Anderson Cancer Center Radiation-associated and sporadic UPS/MFH: Searching for novel therapeutic strategies.

E2F3 in Soft Tissue Sarcoma Development M. Scurr; A Feber; J Shipley; A Fletcher; N Dennis; I Judson; C Cooper.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Kerrington Smith, M.D. CTOS Nov 14, 2008

Example RTK: EGF receptor

12 th Annual CTOS Meeting 2006 SESSION 11 Molecular biology for the patients: Define new targets? Predict Outcome? Moderators: Ole Steen Nielsen & Irene.

Kyoto University, Japan

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

The desmoid tumor proteome: identifying molecular markers using a clinically annotated tissue microarray Shohrae Hajibashi, Wei-Lien Wang, Alexander J.F.

The ERK- MAP Kinase-PEA3-MMP-1 axis is operative in Oesophageal Adenocarcinoma Yeng Ang Consultant Gastroenterologist, Salford Royal University NHS FT.

Here are some CML slides that may be helpful for your presentation.

Combined Experimental and Computational Modeling Studies at the Example of ErbB Family Birgit Schoeberl.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,

Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.

HOMING Ewing vs Paget Trapping vs homing (controlled arrest) “Seed and soil” Organ-specific metastatic colonization of favorable microenvironment.

MECHANISM OF ACTION STUDIES IN A549 CELLS SHOW THAT MARCKS-INHIBITORY PEPTIDES (IN THIS CASE MANS PEPTIDE) BLOCKS PHOSPHORYLATION OF MARCKS IN RESPONSE.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%

FOCUS INTERGROUP COLLABORATION AGAINST SARCOMAS (ICAS) FOCUS Biologically targeted therapeuticsBiologically targeted therapeutics Histology specificHistology.

Integrin-EGFR Cross-Activation Elizabeth Brooks Department of Chemical Engineering University of Massachusetts, Amherst Peyton Lab Group Meeting December.

TGFβ-Receptor 1/ALK5 NEIL MEHTA BIOL

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

Are macrophages interesting targets for anti-cancer therapy?

Angiotensin signalling in GBM: AT2R as a novel therapeutic target

Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Multidrug resistance drives partial EMT to complete EMT: study the network of EMT mediators 楊毅輝1*、陳奇雍2、孟子青３、王正康4# １國所防醫學院醫學系，２國防醫學院生命科學研究所，３國防醫學院生物化學研究所，4中央研究院生物化學研究.

Peyton Rous discovered a virus that causes cancer in chickens

Targeting signal transduction

Inducing Angiogenesis

Activating Invasion and Metastasis

Activating Invasion and Metastasis

Inhibitor of MAP kinase activation blocks colon cancer growth

Underlying Mechanisms for Distant Metastasis - Molecular Biology

Microenviornment Model

Microenvironment Model

Figure 1 A schematic representation of the HER2 signalling pathway

Cell Physiol Biochem 2016;39: DOI: /

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Rad51 over-expression contributes to chemoresistance in human STS; A role for p53/AP2 transcriptional regulation J. Hannay, J. Liu, S. Bolshakov, D. Yu,

Vascular Endothelial Growth Factor (VEGF) Pathway

Met as a therapeutic target in HCC: Facts and hopes

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

SRC and STAT Pathways Journal of Thoracic Oncology

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

Signaling by Ras/Raf/ERK in the regulation of β-cell proliferation.

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer Gengpeng Lin, MD, Longhua Sun,

Simplified BRAF signaling network.

The Role of TIPE2 Protein in Invasive Breast Carcinoma

EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.

Presentation transcript:

The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng Zhu, Alexander J.F. Lazar, Raphael E. Pollock, Dina C. Lev Presented by Gonzalo Lopez, MS Sarcoma Research Laboratory MD Anderson Cancer Center Houston, TX

Complex karyotype: Leiomyosarcoma MFH/UPS MPNST Generally poor prognosis Sarcomas are heterogeneous

Migration and invasion critical for STS metastasis Primary tumor Proliferation/ angiogenesis Migration /invasion Embolism/circulation Transport Arrest in organs Adherence to vessel wall Extravasation Establishment of a microenvironment Proliferation/ angiogenesis Metastasis What are the molecular drivers of these processes???

Candidate mechanisms: receptor tyrosine kinases (RTK) RTKs: c-Met, EGFR, VEGFR, c-Kit, etc.RTKs: c-Met, EGFR, VEGFR, c-Kit, etc. RTKs: central components of signaling networks (embryogenesis, cell proliferation, apoptosis)RTKs: central components of signaling networks (embryogenesis, cell proliferation, apoptosis) RTK deregulation: diabetes, developmental defects, and cancerRTK deregulation: diabetes, developmental defects, and cancer Activated RTKs: induce pathways of cell migration and invasion

c-Met receptor: relevant biology Found in mesenchymal and epithelial tissues Found in mesenchymal and epithelial tissues Ligand HGF (hepatocyte growth factor) Ligand HGF (hepatocyte growth factor) Involved in embryogenesis, wound healing Involved in embryogenesis, wound healing Broad range of downstream effects Broad range of downstream effects

c-Met receptor WG Jiang et al. 2005

Experimental goal To evaluate the impact of c-Met activation and inhibition on complex karyotype STS migration and invasion

c-Met is expressed in human STS tissue Leiomyo/UPS TMA MPNST TMA

Phospho c-Met HGF Total c-Met Phosphorylated c-Met correlates with dismal outcome (HR 2.32; p=0.012)

c-Met is expressed in human STS cell lines c-Met SKLMS1 HT1080 A204 RD MES-SA SW684 SW872 NHF  -actin c-Met p c-Met HT1080SKLMS1A HGF

Birchmeier,C. Nature Reviews. 2003

HGF activates ERK and AKT p c-Met c-Met β-actin p AKT AKT p ERK ERK SKLMS1A HGF

A204 SKLMS1 HGF induces migration HGF induces migration HGF - + Avg. # of cells/HPF HGF (-) HGF (+) SKLMS1

HGF induces invasion HGF induces invasion A204 SKLMS1 HGF - + HGF (-) HGF (+) Avg. # of cells/HPF SKLMS1

Small molecule inhibitor (PHA , Pfizer) Anti c-Met siRNA Inhibition of c-Met

PHA inhibits c-Met activation and downstream signaling c-Met p c-Met ERK pERK pAKT AKT HGF PHA 1 uM 2.5 uM 5 uM

MockNTsiRNA c-Met siRNA effect on downstream signaling c-Met p c-Met ERK pERK pAKT AKT HGF

DMSOPHA HGF - + DMSODMSO + HGFPHA PHA + HGF c-Met blockade abrogates HGF induced invasion Avg. # of cells/HPF

- HGF + HGF FN1 ITGB5 LAMB1 LAMA5 MMP2 GAPDH - + HGF LAMB1 LAMA5 ITGB5 FN1 HGF induces migration and invasion genes

Conclusions Human STS samples highly express c-Met, HGF, and activated c-MetHuman STS samples highly express c-Met, HGF, and activated c-Met Activated c-Met expression correlates with dismal outcome in MPNSTActivated c-Met expression correlates with dismal outcome in MPNST Activation of c-Met receptor on STS inducesActivation of c-Met receptor on STS induces migration and invasion migration and invasion c-Met blockade abrogates these processesc-Met blockade abrogates these processes

Acknowledgements Sarcoma Research Laboratory at UTMDACC  Dina C. Lev, MD  Raphael E. Pollock, MD/PhD  Alex J.F. Lazar, MD/PhD  Sarah E. Myers, BS  Wenhong Ren, MD  Colleagues and Staff